Copyright
©The Author(s) 2023.
World J Gastroenterol. May 28, 2023; 29(20): 3133-3144
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3133
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3133
Table 3 Adverse events and patient compliance
| Variable | % |
| Adverse events | |
| Total adverse events | 14.7% (10/68) |
| Dry mouth | 1.5% (1/68) |
| Skin rash | 4.4% (3/68) |
| Bloating | 1.5% (1/68) |
| Diarrhea | 5.9% (4/68) |
| Abdominal pain | 1.5% (1/68) |
| Grade of adverse event | |
| Mild | 70.0% (7/10) |
| Moderate | 30.0% (3/10) |
| Severe | 0% (0/10) |
| 1Compliance | |
| Good | 95.6% (65/68) |
| Poor | 4.4% (3/68) |
- Citation: Yu J, Lv YM, Yang P, Jiang YZ, Qin XR, Wang XY. Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection. World J Gastroenterol 2023; 29(20): 3133-3144
- URL: https://www.wjgnet.com/1007-9327/full/v29/i20/3133.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i20.3133